Manufacturing Japan-based Nipro Pharma Packaging acquires Croatian manufacturer Piramida

Japan-based Nipro Pharma Packaging acquires Croatian manufacturer Piramida

-

Nipro, a Japanese pharmaceutical packaging firm, has purchased the acquisition of Piramida, a Croatian glass Pharmaceutical packaging manufacturer. This acquisition will aid Nipro in fulfilling the growing demand for pharmaceutical packaging in Central European markets and will help Piramida to strengthen its status in Europe and other global markets.

The acquisition and transfer of shares to Nipro were conducted by Blue Sea Capital, a private investment firm. The transaction’s financial terms have not yet been revealed.

Yoshihiko Sano, President of Nipro said: “This latest acquisition demonstrates that Nipro takes its role and responsibility to society at large seriously.
“Extending our manufacturing footprint is of the utmost importance when supply continuity may be at stake.”
Kresimir Sečak, CEO of Piramida said: “Our management team is looking forward to working with Nipro to further advance Piramida’s position in the European and global markets.”
Piramida is capable of manufacturing over 500 million glass containers per year.
Blue Sea Capital acquired the company in 2012. Since then, it has invested in renovating its facilities and adding eight new manufacturing lines.
The vials and ampoules company of Piramida has expanded under the acquisition of Blue Sea Capital, propelling it to the top five ampoules manufacturing firms in Europe’s Pharmaceutical market.
The European Bank for Reconstruction and Development (EBRD) granted the firm a loan of €3.6 million in 2013, which was partially invested in establishing new manufacturing facilities.
Saša Galić, the managing partner of Blue Sea Capital said: “We are proud that Piramida has attracted the interest of one of the leading global players in the pharmaceutical packaging industry.
“We are excited to watch Piramida enter a new phase of growth with global ambitions.”

Latest news

Zealand Pharma and Iktos collaborate to develop AI Technology for Peptide drug design

Specialists in artificial intelligence for new drug design, Iktos announced a research partnership with Zealand Pharma to...

UK’s NICE makes recommendation for Imlifidase by Hansa Biopharmaceutical

With the National Institute for Health and Care Excellence’s (NICE) recommendation for the use of imlifdase, over...

Heart failure drug by Cytokinetics delayed – FDA wants more time to review

The Food and Drug Administration requires more time to study Cytokinetics’ omecamtiv mecarbil following analysis of some...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you